10607 results for 'phospho antibody'

Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha

Key Facts About VibostolimabWhat is Vibostolimab?Vibostolimab is an anti-TIGIT monoclonal antibody developed by Merck, targeting immune checkpoint pathways to enhance anti-tumor immunity

Quick Facts About RuplizumabWhat is Ruplizumab?Ruplizumab is an investigational monoclonal antibody designed to target CD47, a protein that helps cancer cells evade immune detection.What

Quick Facts About SirexatamabWhat is Sirexatamab?Sirexatamab is an investigational monoclonal antibody designed to target CD47, a key immune checkpoint involved in cancer evasion.How Doe

Quick Facts About ApamistamabWhat is Apamistamab?Apamistamab is a monoclonal antibody that targets the CD45 antigen on hematopoietic cells.How does Apamistamab work?When labeled with the

Transplant rejection is the fastest, most violent adaptive immune response a body can mount — and it is a response to a molecule rather than to a pathogen. Somewhere between one and ten per cent of a

Immunology · Cell BiologyCells of the Innate Immune System: Types, Functions and MarkersThe innate immune system responds within minutes, without prior exposure, using cells that recognise conserved m

Quick Facts About Rovalpituzumab TesirineWhat is Rovalpituzumab Tesirine?Rovalpituzumab Tesirine (Rova-T) is an antibody-drug conjugate (ADC) designed to target DLL3, a protein overexpre

HER2 has no ligand. HER3 has no kinase. Together they are the most potent signalling pair in human biology. That single sentence explains most of what is strange about this receptor family and all of

Introduction to SLAMF7 in Cancer Immunotherapy SLAMF7, also known as Signaling Lymphocytic Activation Molecule F7, is a surface receptor found on natural killer (NK) cells, T cells, plasm

Quick Facts About IanalumabWhat is Ianalumab?Ianalumab is a monoclonal antibody currently being investigated for its potential in treating autoimmune diseases, particularly lupus and imm

Quick Facts About UlocuplumabWhat is Ulocuplumab?Ulocuplumab is an investigational monoclonal antibody targeting CXCR4, a chemokine receptor involved in tumor progression and immune cell

Quick Facts About IcrucumabWhat is Icrucumab?Icrucumab is a monoclonal antibody that targets vascular endothelial growth factor receptor-1 (VEGFR-1) to inhibit tumor angiogenesis.How Doe

Apoptosis is not one pathway but three routes into the same execution machinery. A death ligand at the surface, a mitochondrion that loses outer-membrane integrity, and a granzyme delivered by a cyto

The fight against B cell cancers, a challenging spectrum of hematologic malignancies, has entered a new era with the introduction of rituximab biosimilars. These biosimilars promise to extend the

Immune evasion is one of the hallmarks of cancer, where tumor cells employ various strategies to suppress immune responses and prevent destruction by the body’s defense systems. CD200, a

Quick Facts About BelimumabWhat is Belimumab?Belimumab is a monoclonal antibody used to treat systemic lupus erythematosus (SLE), an autoimmune disease. It is marketed under the brand na

A chimeric antigen receptor is a synthetic protein wired into a real signalling pathway. The extracellular half is an antibody fragment; everything below the membrane is borrowed from the T-cell rece

Introduction to BTLA in Immune Regulation B and T lymphocyte attenuator (BTLA) is an immune checkpoint molecule that plays a critical role in regulating immune responses by suppressing T